Sun Pharma, Lupin recall drugs in US over manufacturing issues: USFDA
Lupin have recalled their products in the US market over manufacturing issues, as per the US Food and Drug Administration (USFDA). Mumbai-based Sun Pharmaceutical Industries is recalling 96,192 bottles of Liothyronine Sodium Tablets in the US that are used to treat an underactive thyroid. The company is recalling the lot due to "failed impurities/degradation specifications", the USFDA stated.
IPCA, CIPLA, JB Chemicals, Sun lead Indian Pharma market growth during November Princeton-based Sun Pharmaceutical Industries Inc, a unit of the company, is recalling the affected lot that was produced at the Dadra-based facility. Sun Pharma commenced the voluntary nationwide Class II recall on December 4, this year. Delhi High Court grants interim relief to Sun Pharma in ‘Abzorb’ trademark case US Food and Drug Administration stated that Mumbai-based Lupin is also recalling an unspecified number of penicillamine tablets in the US.
The medication is used to treat rheumatoid arthritis and Wilson's disease. Baltimore-based Lupin Pharmaceuticals Inc, a unit of the company, is recalling the affected lot that was produced at the drugmaker's Nagpur-based facility. Lupin Q2 results: Net profit jumps 277% to ₹490 crore As per the USFDA, the company is recalling the affected lot due to "failed dissolution specifications".
The company initiated the Class II nationwide (US) voluntary recall on November 22. As per the USFDA, a class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Lupin's Madhya Pradesh facility receives EIR from USFDA The Indian
. Read more on livemint.com
